C M Bidwell & Associates LTD Phathom Pharmaceuticals, Inc. Transaction History
C M Bidwell & Associates LTD
- $189 Million
- Q2 2025
A detailed history of C M Bidwell & Associates LTD transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, C M Bidwell & Associates LTD holds 1,122 shares of PHAT stock, worth $13,396. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,122Holding current value
$13,396% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding PHAT
# of Institutions
137Shares Held
60.5MCall Options Held
1.35MPut Options Held
1.19M-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$149 Million6.31% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$89.1 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA4.14MShares$49.4 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$41.8 Million41.56% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$34.9 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $468M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...